ADHD Prevalence Was Steady in U.S. Youth From 2017 to 2022
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, Oct. 6, 2023 -- The prevalence of attention-deficit/hyperactivity disorder (ADHD) in U.S. youth remained steady from 2017 to 2022, according to a research letter published online Oct. 4 in JAMA Network Open.
Yanmei Li, from Guangdong Pharmaceutical University in Guangzhou, China, and colleagues estimated the prevalence and trends of ADHD among children and adolescents (aged 4 to 17 years) in the United States from 2017 to 2022 using data from the National Health Interview Survey (37,609 individuals).
The researchers found that 10.9 percent reported to have ever been diagnosed with ADHD, with no significant annual change noted in prevalence (10.0 percent in 2017 and 10.8 percent in 2022). Prevalence did significantly vary by sociodemographic factors. In 2021 to 2022, ADHD prevalence was significantly higher in girls versus boys, those aged 12 to 17 years versus 4 to 11 years, White individuals versus Hispanic or Black individuals, and those living in poverty versus higher income.
"Given that the estimated ADHD prevalence was still high, further investigation is warranted to assess potentially modifiable risk factors and provide adequate resources for treatment of individuals with ADHD in the future," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.